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Synthesis of melittin-loaded nanoparticles and their interactions with red blood cells and cancer cells. (A) TEM of liposomes and perfluorocarbon 
nanoparticles before and after incorporation of melittin (lipid/melittin molar ratio, 40). Note the disruption of liposomes and the stable insertion 
of melittin into nanoparticles. Also shown are the freeze-fracture transmission electron micrographs of the hemifusion between a lipid mono-
layered nanoparticle and bilayered liposome. Scale bars: 200 nm. (B) Melittin-loaded nanoparticles (melittin NP) display reduced lysis of red 
blood cells. A standard hemolysis assay was performed on fresh umbilical cord blood (see Methods). Free melittin is highly lytic to red cells with 
an IC50 of 0.51 μM. (C) Melittin-loaded nanoparticles kill cancer cells. A 12-hour B16F10 melanoma cell proliferation was determined by MTT 
assay. Incorporation of melittin onto nanoemulsions produces a 7-fold protection from free peptide (IC50 of 0.7 μM for free melittin vs 5.1 μM for 
nanoemulsions). Data are represented as mean ± SD.
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Pharmacokinetics and biodistribution of melittin-loaded nanoparticles. (A) 
The clearance of 1 mg/kg Tc-labeled melittin injected i.v. (either free or 
on nanoparticles) from circulation (n = 3). A 2-compartment biexponen-
tial model was fit to the data. Note the rapid elimination of free melittin 
and the prolonged circulation of melittin-loaded nanoparticles (elimination 
time ≈ 330 minutes). (B) The biodistribution of 1 mg/kg Tc-labeled melittin 
injected i.v. (either free or on nanoparticles) after 2 hours (n = 3–4). Most 
of the free Tc-labeled melittin is in the spleen, liver, and lungs.
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Therapeutic efficacy of melittin-loaded nanoparticles in syngeneic B16F10 mouse melanoma tumors. (A) Graph showing the increase in tumor 
volume of B16F10 melanoma tumors during the course of treatment with melittin-loaded nanoparticles (8.5 mg/kg) or controls (saline or nanopar-
ticles alone; n = 5 each group). Note the dramatic difference in tumor volume at day 14 after 4 doses of melittin-loaded nanoparticles. Data 
are represented as mean ± SD. **P < 0.01. (B) Histological assessment of B16F10 melanoma tumors excised at day 14. Note the extensive 
nonproliferating dead areas in the treated tumors along with the markedly decreased vascularity. Arrows indicate blood vessels in the H&E and 
CD31 photographs and dead areas in the BrdU photographs.
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Human melanoma (C32) cells  that express  the αvβ3  integ-




















Delivery of melittin from integrin αvβ3–targeted nanoparticles to endothelial cells and cancer cells. (A and B) A 5-fold reduction in IC50 after spe-
cific targeting of melittin-loaded nanoparticles to endothelial cells and melanoma cells. 3-hour cell proliferation was determined by the MTT assay 
(see Methods). Incorporation of melittin onto nanoparticles produces a 25-fold protection from free peptide (IC50 of 1–2 μM for free melittin and 
greater than 25 μM for nontargeted nanoparticles). Specific targeting of the nanoparticles to αvβ3 integrins produces a 5-fold enhancement of 
melittin toxicity; IC50, 6–8 μM. Data are represented as mean ± SD. (C and D) A typical permanganate-fixed transmission picture (left) and plati-
num replica images (right) of C32 melanoma cells interacting with either nontargeted (C) or αvβ3 integrin–targeted nanoparticles (D). (E) Selected 
higher magnification platinum replica images of nanoparticles on the plasma membrane and microvilli of C32 melanoma cells. Left 2 panels show 
nontargeted nanoparticles, and the right 2 panels show αvβ3 integrin–targeted nanoparticles attached to microvilli. Scale bars: 200 nm.
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Release of cytochrome c (cyt c) and induction of apoptosis by αvβ3 integrin–targeted melittin-loaded nanoparticles. (A) Effect of αvβ3 targeting 
on the association of fluorescein-melittin with C32 melanoma cells in culture visualized by confocal microscopy. Cells were exposed to fluores-
cein-melittin at 37°C. Scale bar: 20 μm. (B) A single C32 melanoma cell reconstruction using the T3D package in NEOSYS. This allows viewing 
both the cell surface and intracellular distribution of the fluorescein-melittin after incubation at 37°C. (C) C32 melanoma cells were treated with 
the indicated concentration of melittin on αvβ3 integrin–targeted nanoparticles. Apoptosis was determined by flow cytometry. Cells stained with 
annexin V–FITC only were considered early in apoptosis and those stained with annexin V–FITC and 7-AAD were late apoptotic cells. Data 
are represented as mean ± SD. n = 3. (D) Comparison of cytochrome c release from mitochondria and extracellular release of LDH. Data are 
represented as mean ± SD. n = 3. *P < 0.05; **P < 0.01.
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Hemoglobin (gm%) 11.62 ± 0.62 11.7 ± 0.72
Alanine transaminase (U/l) 73.4 ± 18.63 69.8 ± 11.12
AST (U/l) 62.5 ± 15.3 82.25 ± 14.84
Alkaline Phosphatase (U/l) 35.8 ± 8.56 54.4 ± 12.89
Creatinine kinase (U/l) 152.2 ± 110.9 138.4 ± 49.18
Blood urea nitrogen (mg%) 18.8 ± 2.28 21.8 ± 3.11
Glucose (mg%) 160.4 ± 17.99 147 ± 12.8
Amylase (U/l) 6116 ± 1877 5806 ± 2366
Albumin (gm%) 2.26 ± 0.23 2.16 ± 0.25
Creatinine (mg%) 0.4 ± 0.05 0.4 ± 0.03
Bilirubin (mg%) 0.1 ± 0.02 0.1 ± 0.01
Potassium (mmol/l) 6.56 ± 0.7 7.67 ± 0.96
Chloride (mmol/l) 105 ± 6.36 106.8 ± 11.12
Sodium (mmol/l) 138.8 ± 6.45 138.5 ± 6.95
AAfter i.v. injection of 7 doses of melittin-loaded nanoparticles (13.5 mg/kg 
melittin) over 24 days.
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Role of cholesterol in the induction of apoptotic cell death by αvβ3 integrin–targeted melittin-loaded nanoparticles. (A) C32 melanoma cells were 
treated with 2 concentrations of methyl-β-cyclodextrin (MBCD) to remove cholesterol as described in Methods and in Results. These cells were 
washed and exposed to the αvβ3 integrin–targeted nanoparticles. After incubation in culture, cell proliferation was determined by MTT assay 
as described in Methods. Data are represented as mean ± SD. **P < 0.01. (B–G) Cells treated as described in A were stained with annexin V– 
FITC and 7-AAD before analysis by cell sorting after treatment with the nanoparticles: (B) nanoparticles; (C) 2.5 μM αvβ3 integrin-targeted 
melittin-loaded nanoparticles; (D) 0.25 mM MBCD; (E) 0.5 mM MBCD; (F) 0.25 mM MBCD and 2.5 μM αvβ3 integrin–targeted melittin-loaded 
nanoparticles; and (G) 0.5 mM MBCD and 2.5 μM αvβ3 integrin–targeted melittin-loaded nanoparticles. Cells stained with annexin V–FITC were 
considered early in apoptosis, and those stained with 7-AAD also were late apoptotic cells. Numbers show the percentage of cells in the respec-
tive quadrants. (H) Schematic depiction of interaction of C32 melanoma cells with αvβ3 integrin–targeted melittin-loaded nanoparticles.
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Regression of precancerous epidermal dysplatic lesions in the ears of K14-HPV16 mice by αvβ3 integrin–targeted melittin-loaded nanoparticles. 
(A) Fluorescence microscopy pictures of mouse ear sections showing the extensive overlay with FITC-lectin (shown by arrows) of αvβ3 integ-
rin–targeted rhodamine-nanoparticles compared with nontargeted ones. (B) Representative H&E-stained pictures of K14-HPV16 mouse ear 
sections after treatment with 7 doses of melittin-loaded nanoparticles (melittin dose, 13 mg/kg). Note the regression of papillae (shown by arrows) 
in the group treated with αvβ3 integrin–targeted melittin-loaded nanoparticles. Scale bars: 100 μm (C) Chart showing the specific effect of targeted 
melittin-loaded nanoparticles on regression of severe papillae (greater than 100 μm). Data are represented as mean ± SEM. n = 5. *P < 0.05.
Downloaded on August 23, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/38842
technical advance
























































































































Downloaded on August 23, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/38842
technical advance






















































































































Cell proliferation inhibition assay. The effect of αvβ3  integrin–targeted 
melittin-loaded nanoparticles on mouse endothelial (2F2B) and human 
melanoma (C32) cancer cell proliferation was determined by the MTT 
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